Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Illumina, Inc.
  6. Summary
    ILMN   US4523271090

ILLUMINA, INC.

(ILMN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2021 11/22/2021 11/23/2021 11/24/2021 11/26/2021 Date
379.34(c) 377.15(c) 365.74(c) 365.56(c) 369.79(c) Last
1 051 696 743 120 1 076 736 1 112 787 668 913 Volume
+0.91% -0.58% -3.03% -0.05% +1.16% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 4 424 M - -
Net income 2021 673 M - -
Net Debt 2021 225 M - -
P/E ratio 2021 84,4x
Yield 2021 -
Sales 2022 4 953 M - -
Net income 2022 522 M - -
Net cash position 2022 596 M - -
P/E ratio 2022 109x
Yield 2022 -
Capitalization 57 798 M 57 798 M -
EV / Sales 2021 13,1x
EV / Sales 2022 11,5x
Nbr of Employees 7 825
Free-Float 79,8%
More Financials
Company
Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina's products and services serve customers in the... 
More about the company
Ratings of Illumina, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about ILLUMINA, INC.
11/25Vitrolife To Distribute Genomic Testing Kits In Asia Pacific Region
MT
11/24INSIDER SELL : Illumina
MT
11/17Illumina and Sequoia Capital China Select First Startups to join Genomics Incubator in ..
PR
11/17Illumina and Sequoia Capital China Select First Startups to join Genomics Incubator in ..
CI
11/16EU Expected to Raise Objections to Illumina's Completed $8 Billion Grail Purchase
MT
11/16INSIDER SELL : Illumina
MT
11/16Illumina, Genetic Alliance Launch $120 Million Program Expanding Genome Sequencing Acce..
MT
11/16Illumina defends Grail deal; expects EU formal objections on Wednesday
RE
11/16Illumina and Genetic Alliance Launch $120 Million Global Initiative to Increase Equity ..
PR
11/08Baird Adjusts Illumina's Price Target to $437 From $493, Maintains Neutral Rating
MT
11/05INSIDER SELL : Illumina
MT
11/04Illumina Posts Higher Q3 Earnings, Revenue -- Stock Up
MT
11/04Earnings Flash (ILMN) ILLUMINA Reports Q3 EPS $1.45, vs. Street Est of $1.22
MT
11/04Earnings Flash (ILMN) ILLUMINA Reports Q3 Revenue $1.11B, vs. Street Est of $1.045B
MT
11/04GUIDANCE : (ILMN) ILLUMINA Forecasts Fiscal Year 2021 EPS Range $5.50 - $5.60
MT
More news
News in other languages on ILLUMINA, INC.
11/25Vitrolife va distribuer des kits de test génomique dans la région Asie-Pacifique
11/16Illumina et Genetic Alliance lancent un programme de 120 millions de dollars pour élarg..
11/16Illumina défend l'accord Grail et s'attend à recevoir des objections formelles de l'UE ..
11/05VENTE D'INITIÉS : Illumina
11/04Illumina affiche des résultats et un chiffre d'affaires plus élevés au troisième trimes..
More news
Analyst Recommendations on ILLUMINA, INC.
More recommendations
Chart ILLUMINA, INC.
Duration : Period :
Illumina, Inc. Technical Analysis Chart | ILMN | US4523271090 | MarketScreener
Technical analysis trends ILLUMINA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Last Close Price 369,79 $
Average target price 441,73 $
Spread / Average Target 19,5%
EPS Revisions
Managers and Directors
Francis A. deSouza President, Chief Executive Officer & Director
Sam A. Samad Chief Financial Officer & Senior Vice President
John Wendell Thompson Chairman
Phillip G. Febbo Chief Medical Officer
Alex Aravanis CTO, Head-Research & Product Development
Sector and Competitors